AstraZeneca | AZN

Stock Price
15,270.00
Daily Change
-20.00 -0.13%
Monthly
12.61%
Yearly
29.71%
Q1 Forecast
14,964.60



Peers Price Chg Day Year Date
AbbVie 224.81 0.46 0.21% 11.25% Feb/20
Alcon AG 64.28 0.36 0.56% -20.88% Feb/20
Almirall 13.42 -0.28 -2.04% 47.23% Feb/20
Amgen 374.75 -0.75 -0.20% 23.68% Feb/20
argenx SE 722.40 4.80 0.67% 16.67% Feb/20
Autolus Therapeutics Ltd 1.67 0.03 1.83% -14.36% Feb/20
AstraZeneca 15,270.00 -20.00 -0.13% 29.71% Feb/21
Bayer 43.68 -1.90 -4.16% 96.09% Feb/21
Biogen 192.03 -0.05 -0.03% 36.54% Feb/20
Bristol-Myers Squibb 60.66 0.36 0.60% 8.65% Feb/20

Indexes Price Day Year Date
GB100 10687 59.85 0.56% 23.41% Feb/20
EU600 631 5.23 0.84% 13.85% Feb/20
US100 25013 215.28 0.87% 15.72% Feb/20

AstraZeneca traded at 15,270.00 this Saturday February 21st, decreasing 20.00 or 0.13 percent since the previous trading session. Looking back, over the last four weeks, AstraZeneca lost 12.61 percent. Over the last 12 months, its price rose by 29.71 percent. Looking ahead, we forecast AstraZeneca to be priced at 14,964.60 by the end of this quarter and at 14,084.56 in one year, according to Trading Economics global macro models projections and analysts expectations.

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.



News Stream
AstraZeneca Stock Price Hits 7-week High
AstraZeneca shares increased to 14412.00 GBp, the highest since December 2025. Over the past 4 weeks, AstraZeneca gained 1.9%, and in the last 12 months, it increased 21.91%.
2026-02-11
AstraZeneca Stock Price Hits 10-week Low
AstraZeneca shares decreased to 13278.00 GBp, the lowest since November 2025. Over the past 4 weeks, AstraZeneca lost 2.58%, and in the last 12 months, it increased 20.16%.
2026-01-20
AstraZeneca Stock Price Hits 7-week Low
AstraZeneca shares decreased to 13362.00 GBp, the lowest since November 2025. Over the past 4 weeks, AstraZeneca lost 1.44%, and in the last 12 months, it increased 24.93%.
2026-01-05